Literature DB >> 27310575

Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery.

Stéphanie Eustache1, Jérôme Leprince2, Pierre Tufféry1.   

Abstract

INTRODUCTION: Peptides have gained renewed interest as candidate therapeutics. However, to bring them to a broader clinical use, challenges such as the rational optimization of their pharmacological properties remain. Peptide scanning techniques offer a systematic framework to gain information on the functional role of individual amino acids of a peptide. Due to progress in mastering new chemical synthesis routes targeting amino acid backbone, they are currently diversified. Structure-activity relationship (SAR) analyses such as alanine- or enantioneric- scanning can now be supplemented by N-substitution, lactam cyclisation- or aza-amino scanning procedures addressing not only SAR considerations but also the peptide pharmacological properties. AREAS COVERED: This review highlights the different scanning techniques currently available and illustrates how they can impact drug discovery. EXPERT OPINION: Progress in peptide scanning techniques opens new perspectives for peptide drug development. It comes with the promise of a paradigm change in peptide drug design in which peptide drugs will be closer to the parent peptides. However, scanning still remains assimilable to a trial and error strategy that could benefit from being combined with specific in silico approaches that start reaching maturity.

Entities:  

Keywords:  Ala-; Aza-amino; D-; N-alkyl scanning; Peptide drug development; Peptide scanning; Positional-; Pro-; gamma-lactam

Mesh:

Substances:

Year:  2016        PMID: 27310575     DOI: 10.1080/17460441.2016.1201058

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  5 in total

Review 1.  The Arg-Phe-amide peptide 26RFa/glutamine RF-amide peptide and its receptor: IUPHAR Review 24.

Authors:  Jérôme Leprince; Didier Bagnol; Ronan Bureau; Shoji Fukusumi; Riccarda Granata; Shuji Hinuma; Dan Larhammar; Stefany Primeaux; Jana Sopkova-de Oliveiras Santos; Kazuyoshi Tsutsui; Kazuyoshi Ukena; Hubert Vaudry
Journal:  Br J Pharmacol       Date:  2017-09-08       Impact factor: 8.739

Review 2.  Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.

Authors:  Isabelle Aillaud; Susanne Aileen Funke
Journal:  Cell Mol Neurobiol       Date:  2022-05-21       Impact factor: 5.046

3.  PEG-BHD1028 Peptide Regulates Insulin Resistance and Fatty Acid β-Oxidation, and Mitochondrial Biogenesis by Binding to Two Heterogeneous Binding Sites of Adiponectin Receptors, AdipoR1 and AdipoR2.

Authors:  In Kyung Lee; Gyuyoup Kim; Do-Hwi Kim; Brian B Kim
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

Review 4.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14

5.  Identification of Crucial Residues in α-Conotoxin EI Inhibiting Muscle Nicotinic Acetylcholine Receptor.

Authors:  Jiong Ning; Jie Ren; Yang Xiong; Yong Wu; Manqi Zhangsun; Dongting Zhangsun; Xiaopeng Zhu; Sulan Luo
Journal:  Toxins (Basel)       Date:  2019-10-16       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.